Patient: Page 3
-
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023 -
5 noteworthy pharma AI investments in 2023
The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.
By Alexandra Pecci • Dec. 19, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Babson gets one step closer to delivering on Theranos-like blood testing
A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.
By Kelly Bilodeau • Dec. 18, 2023 -
Study suggests PBMs are gaming pharmacy system to overcharge for drugs
Markups for generics can be as high as 7,000%, the researchers said.
By Alexandra Pecci • Dec. 15, 2023 -
Q&A
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
By Michael Gibney • Dec. 14, 2023 -
What’s being done to prepare for the next pandemic?
Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.
By Kelly Bilodeau • Dec. 13, 2023 -
Q&A
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
By Meagan Parrish • Dec. 13, 2023 -
Q&A
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023 -
Oncology drugmakers seek the sweet spot between efficacy and tolerability
The FDA is now pushing companies to find the optimal dose early in development to minimize harm.
By Kelly Bilodeau • Dec. 11, 2023 -
Q&A // First 90 Days
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
By Alexandra Pecci • Dec. 11, 2023 -
Sponsored by MedAdvisor Solutions
Increasing inflation means harder medication decisions for patients
Explore strategies for life sciences brands to simplify medication journeys for success through MedAdvisor Solutions’ THRIV™ platform, offering up to 5x more lift in adherence.
Dec. 11, 2023 -
The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.
A look at the fast-evolving pipeline for gene editing therapies.
By Meagan Parrish • Dec. 8, 2023 -
Real Chemistry’s CEO on biopharma’s outlook in 2024
Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.
By Michael Gibney • Dec. 7, 2023 -
The digital therapeutics revolution is here. Will payers play ball?
Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.
By Kelly Bilodeau • Dec. 5, 2023 -
The weight loss market looks unstoppable. How high could it go?
Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.
By Kelly Bilodeau • Dec. 4, 2023 -
Sponsored by AstraZeneca
Transforming blood cancer care to make a difference for patients
AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.
Dec. 4, 2023 -
3 standout digital innovations in pharma this year
IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.
By Meagan Parrish • Dec. 1, 2023 -
Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help
A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.
By Kelly Bilodeau • Nov. 29, 2023 -
Q&A
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
By Michael Gibney • Nov. 28, 2023 -
As alcohol-related deaths climb, new drugs could curb the urge to drink
A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.
By Kelly Bilodeau • Nov. 27, 2023 -
Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
By Kelly Bilodeau • Nov. 20, 2023 -
Q&A
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
By Michael Gibney • Nov. 16, 2023 -
The power of genomics-based healthcare remains largely untapped
23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.
By Alexandra Pecci • Nov. 15, 2023 -
6 ways to improve clinical trial diversity — as shown by J&J
Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.
By Alexandra Pecci • Nov. 14, 2023 -
Deep Dive
What if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023